Powered by

Genesis Therapeutics Enters AI-driven, Multi-Target Drug Discovery Partnership with Genentech; Collaboration will leverage Genesis' state-of-the-art neural network platform

Oct 19, 2020 - Business Wire

Genesis Therapeutics , a privately-held company inventing and deploying state-of-the-art artificial intelligence (AI) techniques to augment drug discovery and development, today announced that it has entered into a multi-target collaboration agreement with Genentech, a member of the Roche Group . The collaboration leverages Genesis' graph machine learning and drug discovery expertise to identify innovative drug candidates for therapeutic targets in multiple disease areas. Genesis will receive an...